Table 2

Effect sizes of subgroups within included treatment comparisons on work participation outcome domains

Sick leaveWork statusPresenteeism
Treatment comparisons (N)SMD (95% CI)Treatment comparisons (N)SMD (95% CI)Treatment comparisons (N)SMD (95% CI)
Overall42−0.23 (−0.33 to −0.13)9−0.38 (−0.63 to −0.12)13−0.25 (−0.39 to −0.12)
Disease
Pain syndromes19−0.07 (−0.33 to 0.19)3−0.50 (−0.93 to −0.08)3−0.19 (−0.50 to 0.12)
i/dRMDs23−0.35 (−0.57 to −0.14)6−0.28 (−0.49 to −0.07)9−0.20 (−0.39 to 0.00)
Baseline risk for adverse work outcomes
At risk (on sick leave or other risk)28−0.11 (−0.19 to −0.02)60.03 (−0.52 to 0.59)70.01 (−0.27 to 0.29)
Not at risk (not on sick leave, no other risk)3−0.35 (−0.67 to −0.03)0NA3−0.44 (−0.73 to −0.15)
Mixed risk (on sick leave/not on sick leave)5−0.51 (−0.83 to −0.18)1−0.38 (−0.62 to −0.14)3−0.17 (−0.31 to −0.02)
Risk not described/specified6−0.19 (−0.51 to 0.12)2−0.43 (−0.94 to 0.08)0NA
Setting
Clinical29−0.12 (−0.21 to −0.02)5−0.31 (−0.65 to 0.03)4−0.14 (−0.44 to 0.16)
Workplace1−0.38 (−0.98 to 0.22)0NA3−0.19 −0.63 to 0.25)
Combined (clinical+workplace)1−0.09 (−0.53 to 0.36)0NA2−0.13 (−0.56 to 0.30)
Other11−0.24 (−0.40 to −0.08)4−0.35 (−0.61 to −0.09)4−0.34 (−0.70 to 0.01)
Components
Single11−0.12 (−0.22 to −0.33)2−0.28 (−0.49 to −0.07)3−0.22 (−0.41 to −0.04)
Multiple31−0.25 (−0.42 to −0.08)7−0.51 (−0.93 to −0.08)10−0.09 (−0.44 to 0.27)
  • A negative SMD suggested a beneficial effect in improving the work outcome by the intervention over the control.

  • i/dRMD, inflammatory or degenerative or mixed rheumatic and musculoskeletal disease; NA, no studies included the specified contextual factor for this work outcome domain; SMD, standardised mean difference.